Loading...
OTCM
ULGX
Market cap2kUSD
Sep 08, Last price  
0.00USD
Name

21st North Inc

Chart & performance

D1W1MN
OTCM:ULGX chart
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
3.15%
Revenues
14m
-14.20%
500,000400,0005,500,00011,200,0006,100,0008,163,24915,337,00022,742,00018,775,00024,324,00025,813,00025,885,00021,317,00014,906,00012,816,00014,771,00012,571,00017,027,00016,590,00014,235,000
Net income
-8m
L+77.26%
-5,400,000-7,600,000-8,200,000-15,000,000-14,100,000-7,097,561-5,135,000-1,651,000-10,048,000642,0002,837,0005,494,000-13,237,000-14,897,000-4,419,000-2,169,000-3,733,000-4,695,000-4,292,000-7,608,000
CFO
-2m
L-21.90%
-5,200,000-6,800,000-9,600,000-17,300,000-7,600,000-4,341,633-3,755,000-1,464,000-7,507,0002,892,0002,919,0001,167,0001,496,000-1,045,000-3,921,000-1,255,000-2,370,000-713,000-1,959,000-1,530,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company's innovative solutions target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Among its key offerings is Cooled ThermoTherapy, a system that precisely applies microwave energy while simultaneously employing a cooling mechanism to safeguard healthy tissues and improve patient comfort. Urologix also provides the Prostiva RF Therapy System, which directs radio frequency energy into the prostate gland. This process works to eliminate problematic prostatic tissue, consequently easing urethral constriction and alleviating BPH-related discomfort. Urologix, Inc. caters to both healthcare professionals and patients.

Key people

Mitchell Dann
Independent Non-Executive Chairman of the Board, Lead Director · since 2008
Scott Madson
Chief Financial Officer · since 2015
Lisa Ackermann
Executive Vice President - Sales and Marketing · since 2012
Gregory Fluet
Chief Executive Officer, Director · since 2015
Christopher Barys
Independent Director · since 2010
Sidney Emery
Independent Director · since 2005
Patrick Spangler
Independent Director · since 2010
URL
https://www.urologix.com/
IPO date
May 30, 1996
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

No data to show